Predict your next investment

Corporation
HEALTHCARE | Medical Devices & Equipment / Patient Monitoring
omnicell.com

See what CB Insights has to offer

Founded Year

1992

Stage

IPO | IPO

Total Raised

$59.3M

Date of IPO

8/7/2001

Market Cap

7.79B

Stock Price

177.22

About Omnicell

Omnicell (NASDAQ: OMCL) is a provider of medication and supply management solutions and adherence tools to healthcare systems and pharmacies. As a leader in medication and supply dispensing automation, central pharmacy automation, IV robotics, analytics software, and medication adherence and packaging systems, Omnicell is focused on improving care across the entire healthcare continuum - from the acute care hospital setting, to post-acute skilled nursing and long-term care facilities, to the patient's home.

Omnicell Headquarter Location

590 E. Middlefield Road

Mountain View, California, 94043,

United States

650-251-6100

Latest Omnicell News

Smith+Nephew (SNN) Introduces Real Intelligence & CORI System

Nov 25, 2021

Smith+Nephew (SNN) debuts new brand of enabling technology solutions as well as its next-generation handheld robotics platform in Canada. This story originally appeared on Zacks Smith+Nephew SNN recently launched its Real Intelligence brand of enabling technology solutions as well as its next-generation handheld robotics platform, the CORI Surgical System, in Canada. The CORI Surgical System has been approved by Health Canada and is available for sale in the country. - Zacks Through the continuum of care, Real Intelligence will address clinical challenges such as patient engagement, pre-operative planning, digital and robotic surgery, post-operative assessment and outcomes measurement. Every solution in the Real Intelligence digital ecosystem informs the next stage of treatment, allowing healthcare providers to utilize outcomes data in making more informed decisions regarding how they treat their patients over time. The CORI Surgical System, available for both total and unicompartmental knee arthroplasty, will stand at the center of the Real Intelligence brand. Per management, the introduction of CORI Surgical System offers a handheld robotic-assisted platform that is especially well adapted to meet the needs of the Canadian marketplace. More on the CORI System The CORI System eliminates the need for computed tomography (CT) or pre-op imaging. This system has the potential to enhance implant placement accuracy as well as operating room (OR) efficiency. The CORI System is a fraction of the size of other robotic platforms on the market and represents the first step in Smith+Nephew's long-term plan to alter how orthopedic surgeons in Canada treat patients. Image Source: Zacks Investment Research Smith+Nephew intends to continue introducing new applications for this robotics platform, moving beyond knee procedures and into other orthopedic pathologies. In conjunction with intuitive software, the handheld robot helps to size and position the components with accuracy and achieve optimum ligament balance. The entire system is efficient and portable, an ideal combination for a congested OR. Industry Prospects Per a report published in Mordor Intelligence, the robotic-assisted surgery systems market is set to witness a CAGR of 13.6% during 2018-2026. Factors such as increasing technological advancements, entry of new market players, growing burden of chronic disorders and the rising preference for robotic-assisted surgical systems owing to the several advantages associated with them, such as facilitation of precise, tremor-free surgery and benefits of minimally-invasive methods, are fueling market growth. Given the market prospects, the recent Canadian launch of Smith+Nephew’s next-generation handheld robotics platform, the CORI Surgical System, seems well-timed. Notable Developments Smith+Nephew engaged in a number of significant developments in November 2021. The company announced the creation of a purpose-built digital surgery and robotics innovation center in Munich, Germany. The new innovation center will bring together healthcare professionals from EMEA and Smith+Nephew’s R&D and medical education teams to investigate digital surgery and robotics techniques and technologies. At the heart of the innovation center will be Real Intelligence and the new state-of-the-art robotics-assisted surgical system CORI. Smith+Nephew reported the first completed surgical procedures and introduced its LEGION CONCELOC Cementless Total Knee System. CONCELOC Advanced Porous Titanium is a patented, proprietary, 3D printed porous structure technology initially utilized in Smith+Nephew’s REDAPT Revision Hip System. CONCELOC is created in a virtual environment and built via 3D printing additive manufacturing to optimize its porosity structure to promote bone ingrowth. Share Price Performance The stock has underperformed its industry over the past year. It has declined 10.6% compared with the industry’s 2.8% fall. Zacks Rank and Key Picks Currently, Smith+Nephew carries a Zacks Rank #4 (Sell). A few better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. AMN , Varex Imaging Corporation VREX and Omnicell, Inc. OMCL . AMN Healthcare, carrying a Zacks Rank #1 (Strong Buy), has a long-term earnings growth rate of 16.2%. The company surpassed earnings estimates in the trailing four quarters, delivering an average surprise of 19.5%. You can see the complete list of today’s Zacks #1 Rank stocks here. AMN Healthcare has outperformed its industry over the past year. AMN has gained 72.5% against the industry’s 49% fall. Varex, sporting a Zacks Rank #1, has a long-term earnings growth rate of 5%. The company surpassed earnings estimates in the trailing four quarters, delivering an average surprise of 115.3%. Varex has outperformed the industry it belongs to in the past year. VREX has gained 80.9% versus the industry’s 2.9% fall. Omnicell, carrying a Zacks Rank #2 (Buy), has a long-term earnings growth rate of 16%. The company surpassed earnings estimates in the trailing four quarters, delivering a surprise of 17.4%, on average. Omnicell has outperformed its industry over the past year. OMCL has gained 68.4% against the 37% industry decline. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Omnicell

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Omnicell is included in 3 Expert Collections, including Pharma Supply Chain.

P

Pharma Supply Chain

1,357 items

C

Conference Exhibitors

5,302 items

R

Robotics

1,658 items

This collection includes startups developing autonomous ground robots, unmanned aerial vehicles, robotic arms, and underwater drones, among other robotic systems. This collection also includes companies developing operating systems and vision modules for robots.

Omnicell Patents

Omnicell has filed 70 patents.

The 3 most popular patent topics include:

  • Designer drugs
  • Actuators
  • Drug delivery devices
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/8/2018

4/27/2021

Conservation and restoration, Collections care, Museology, Medical equipment, Barcodes

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

1/8/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

4/27/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Conservation and restoration, Collections care, Museology, Medical equipment, Barcodes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Omnicell Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Omnicell Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.